Corbus COO’s Routine “Sell‑to‑Cover” Trade Highlights Steady Executive Confidence in Biotech Pipeline
Corbus Pharmaceuticals’ COO sells 2,415 shares in a routine “sell‑to‑cover” trade, leaving his stake at 51,927 shares – a modest move that signals confidence, not panic, for investors.
- Corbus Pharmaceuticals Holdings Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read